OZEM
Roundhill GLP-1 & Weight Loss ETF
The Roundhill GLP-1 & Weight Loss ETF seeks to provide investment exposure to companies involved in the development and commercialization of GLP-1 therapies and other weight loss solutions.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 56.1 M
ASSETS UNDER MGMT
59 bp
EXPENSES
Fund Basics
| Inception date | May 20, 2024 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 15.8 % |
| NOVO-NORDISK A/S-SPONS ADR | 11.9 % |
| PFIZER INC | 8.4 % |
| KAILERA THERAPEUTICS INC | 5.9 % |
| ASCLETIS PHARMA, INC. | 5.4 % |
| CHINA PHARMACEUTICAL GROUP | 5.2 % |
| CHUGAI PHARMACEUTICAL CO LTD | 5.1 % |
| AMGEN INC | 4.9 % |
| VIKING THERAPEUTICS, INC. | 4.6 % |
| ASTRAZENECA PLC | 4.5 % |
Constituent Breakdown
| Number of holdings | 21 |
| Herfindahl-Hirschman Index | 675 |
| Wgt avg mkt cap (mns) | $228,676 |
| Large cap (>$10bn) | 64.0% |
| Mid cap ($2-10bn) | 13.2% |
| Small cap (<$2bn) | 13.2% |
| Developed mkts. | 85.3% |
| Emerging mkts. | 8.1% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 45.2 % |
 |
DENMARK | 15.4 % |
 |
HONG KONG | 10.7 % |
 |
JAPAN | 6.5 % |
 |
CAYMAN ISLANDS | 5.4 % |
 |
CHINA | 4.8 % |
 |
BRITAIN | 4.5 % |
 |
SOUTH KOREA | 3.6 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -9.9% | 12.7% | 5.6% | -- | -- | -- | -- | 8.6% |
| Dividend Yield | 0.0% | 1.3% | 0.7% | -- | -- | -- | -- | 0.6% |
| Total Returns | -9.9% | 14.0% | 6.4% | -- | -- | -- | -- | 9.2% | Ann. Volatility | 22.6% | 23.1% | 25.1% | -- | -- | -- | -- | 24.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.75 | 17% |
| MSCI EAFE | 0.74 | 26% |
| MSCI Emg Mkts | 0.26 | 8% |
Liquidity Measures
| Avg. volume (000) | 11 |
| ADV traded (mns) | $0 |
| Turnover | 0.6% |
| Avg. Bid/Ask (% of price) | 0.41% |
Technical Indicators
| 30d moving avg. (EMA) | $30.27 |
| Relative strength (RSI) | 47 |
| MACD/Signal | -0.12/-0.32 |
| Bollinger Bands (Upper/Lower) | $30.78/$28.65 |
| Short interest (% of AUM) | 1.9% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. OZEM |
Expenses vs. OZEM |
ALTAR Score™ vs. OZEM |
|---|---|---|---|---|
| THNR | Amplify Weight Loss Drug & Treatment ETF | 64.0% | 0 bp | +1.0% |
| PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | 30.9% | -46 bp | +2.6% |
| MEDX | Horizon Kinetics Medical ETF | 28.7% | +26 bp | -2.1% |
| PPH | VanEck Pharmaceutical ETF | 26.3% | -23 bp | +3.7% |
| XLV | Health Care Select Sector SPDR | 24.3% | -51 bp | +2.7% |
| IYH | iShares U.S. Healthcare ETF | 24.2% | -22 bp | +2.1% |
| IXJ | iShares Global Healthcare ETF | 22.5% | -21 bp | +2.5% |
| VHT | Vanguard Health Care ETF | 22.4% | -50 bp | +1.5% |
| FHLC | Fidelity MSCI Health Care Index ETF | 22.4% | -51 bp | +1.6% |
| HRTS | Tema Heart & Health ETF | 21.4% | +40 bp | -1.5% |
Risk and Returns: OZEM vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/6/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
3.3%
ALTAR SCORE™
28th
PERCENTILE
UNDERWEIGHT
ETFRC RATING
There are 746 funds in the Global Equity category with an average
ALTAR Score™ of 4.8% and a standard deviation
of 2.6%. OZEM's ALTAR Score™ is approximately -0.6 standard
deviations above the category average. This places OZEM in the 28th percentile
among funds in the category.
Sell-Side Consensus
$39.29
PRICE TARGET
+28.2%
UPSIDE